Depending on the definition used, growth retardation occurs in approximately one-third of children presenting with Crohn's disease
Low energy intake and direct effects of inflammation contribute to low height velocity
Compared with the whole paediatric population with Crohn's disease, children carrying Crohn's susceptibility genes do not have increased risk of growth retardation
Inflammatory mediators affect growth by causing growth hormone resistance; resistance is caused by IL-6 and TNF impairing hepatic growth hormone signal transduction and by inhibiting cell proliferation at the growth plate
Medical or surgical resolution of inflammation is the cornerstone of growth retardation treatment; treating inflammation with infliximab or by resection has little efficacy in late puberty (Tanner stage IV or beyond)
Preliminary studies are being carried out on the use of growth hormone and insulin-like growth factor 1 treatment for children whose inflammation proves intractable to medical or surgical intervention
Crohn's disease in childhood causes linear growth retardation, which has a substantial effect on management of this disease. By contrast, growth is rarely a problem in children presenting with ulcerative colitis. Depending on how growth failure is defined, approximately one-third of children with Crohn's disease have growth retardation at diagnosis. Although corticosteroids can suppress growth, decreased height at diagnosis demonstrates that this finding is a consequence of the disease and not merely an adverse effect of treatment. Both inflammation and undernutrition contribute to decreased height velocity. Increased cytokine production acts both on the hepatic expression of insulin-like growth factor 1 (IGF-1) and at chondrocytes of the growth plates of long bones. Growth hormone insensitivity caused by deranged immune function is a major mechanism in growth retardation. Resolution of inflammation is the cornerstone of treatment, but current studies on growth hormone and IGF-1 might yield therapies for those children whose inflammation is refractory to treatment.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sanderson, I. R., Risdon, R. A. & Walker-Smith, J. A. Intractable ulcerating enterocolitis of infancy. Arch. Dis. Child. 66, 295–299 (1991).
Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 (2009).
Sawczenko, A. et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 357, 1093–1094 (2001).
Lowe, A. M. et al. Epidemiology of Crohn's disease in Quebec, Canada. Inflamm. Bowel Dis. 15, 429–435 (2009).
Henderson, P. et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm. Bowel Dis. 18, 999–1005 (2012).
Van Limbergen, J. et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 135, 1114–1122 (2008).
Ballinger, A. B., Savage, M. O. & Sanderson, I. R. Delayed puberty associated with inflammatory bowel disease. Pediatr. Res. 53, 205–210 (2003).
Shamir, R., Phillip, M. & Levine, A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. Inflamm. Bowel Dis. 13, 620–628 (2007).
Snapper, J., Gruen, J. & Foyer, A. Observations sur l'ileite regionale. In Proc. 2nd International Congress of Gastroenterology 935–937 (Societé of Internationale Gastroenterologie, 1937).
Logan, A. H. & Brown, P. W. Intestinal infantilism as a result of regional enteritis. Proc. Mayo Clin. 13, 335–336 (1938).
Pozler, O. et al. Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 42, 186–189 (2006).
Fallahi, G. H. et al. Clinical characteristics of Iranian pediatric patients with inflammatory bowel disease. Acta Gastroenterol. Belg. 72, 230–234 (2009).
Kim, B. J. et al. Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig. Dis. Sci. 55, 1989–1995 (2010).
El-Hodhod, M. A., Hamdy, A. M., Abbas, A. A., Moftah, S. G. & Ramadan, A. A. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol. 12, 44 (2012).
Maisawa, S. et al. Characteristics of inflammatory bowel disease with an onset before eight years of age: a multicenter epidemiological survey in Japan. J. Gastroenterol. Hepatol. 28, 499–504 (2013).
Sawczenko, A., Ballinger, A. B., Savage, M. O. & Sanderson, I. R. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 118, 124–129 (2006).
Griffiths, A. M., Nguyen, P., Smith, C., MacMillan, J. H. & Sherman, P. M. Growth and clinical course of children with Crohn's disease. Gut 34, 939–943 (1993).
Markowitz, J., Grancher, K., Rosa, J., Aiges, H. & Daum, F. Growth failure in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 16, 373–380 (1993).
Hildebrand, H., Karlberg, J. & Kristiansson, B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 18, 165–173 (1994).
Motil., K. J., Grand, R. J., Davis-Kraft, L., Ferlic, L. L. & Smith, E. O. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 105, 681–691 (1993).
Lee, J. J. et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm. Bowel Dis. 16, 1669–1677 (2010).
Alemzadeh, N. et al. Adult height in patients with early onset of Crohn's disease. Gut 51, 26–29 (2002).
Pfefferkorn, M. et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J. Pediatr. Gastroenterol. Nutr. 48, 168–174 (2009).
DeBoer, M. D. & Denson, L. A. Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains. J. Pediatr. 163, 17–22 (2013).
Thayu, M. et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 139, 430–438 (2010).
Abraham, B. P., Mehta, S. & El-Serag, H. B. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J. Clin. Gastroenterol. 46, 581–589 (2012).
Sawczenko, A. & Sandhu, B. K. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch. Dis. Child. 88, 995–1000 (2003).
Vasseur, F. et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am. J. Gastroenterol. 105, 1893–1900 (2010).
Turunen, P. et al. Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study. Inflamm. Bowel Dis. 15, 56–62 (2009).
Mason, A. et al. Impact of inflammatory bowel disease on pubertal growth. Horm. Res. Paediatr. 76, 293–299 (2011).
Timmer, A. et al. Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. J. Pediatr. 158, 467–473 (2011).
Crohn, B. B. Regional Ileitis (Grune & Stratton, 1949).
Gupta, N. et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 120, e1418–e1425 (2007).
Lee, G. J. et al. Role of sex in the treatment and clinical outcomes of pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 55, 701–706 (2012).
Hill, R. J. et al. Ability of commonly used prediction equations to predict resting energy expenditure in children with inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1587–1593 (2011).
Pons, R. et al. Dietary intakes of children with Crohn's disease. Br. J. Nutr. 102, 1052–1057 (2009).
Gerasimidis, K., McGrogan, P. & Edwards, C. A. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J. Hum. Nutr. Diet 24, 313–326 (2011).
El-Haj, T., Poole, S., Farthing, M. J. & Ballinger, A. B. Anorexia in a rat model of colitis: interaction of interleukin-1 and hypothalamic serotonin. Brain Res. 927, 1–7 (2002).
Ates, Y., Degertekin, B., Erdil, A., Yaman, H. & Dagalp, K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig. Dis. Sci. 53, 2215–2221 (2008).
Moran, G. W., Leslie, F. C. & McLaughlin, J. T. Crohn's disease affecting the small bowel is associated with reduced appetite and elevated levels of circulating gut peptides. Clin. Nutr. 32, 404–411 (2013).
Gerasimidis, K., McGrogan, P., Hassan, K. & Edwards, C. A. Dietary modifications, nutritional supplements and alternative medicine in paediatric patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27, 155–165 (2008).
Hill, R. J. et al. Resting energy expenditure in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 45, 342–346 (2007).
Varille, V. et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 23, 13–19 (1996).
Wiskin, A. E. et al. Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease. Clin. Nutr. 28, 652–656 (2009).
Wiskin, A. E., Davies, J. H., Wootton, S. A. & Beattie, R. M. Energy expenditure, nutrition and growth. Arch. Dis. Child. 96, 567–572 (2011).
Winter, T. A., O'Keefe S. J., Callanan, M. & Marks, T. Impaired gastric acid and pancreatic enzyme secretion in patients with Crohn's disease may be a consequence of a poor nutritional state. Inflamm. Bowel Dis. 10, 618–625 (2004).
Ballinger, A. B., Azooz, O., El-Haj, T., Poole, S. & Farthing, M. J. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 46, 694–700 (2000).
Daughaday, W. H. A personal history of the origin of the somatomedin hypothesis and recent challenges to its validity. Perspect. Biol. Med. 32, 194–211 (1989).
Thomas, M. J. The molecular basis of growth hormone action. Growth Horm. IGF Res. 8, 3–11 (1998).
Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V. & Efstratiadis, A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229, 141–162 (2001).
Pass, C., MacRae, V. E., Ahmed, S. F. & Farquharson, C. Inflammatory cytokines and the GH/IGF-I axis: novel actions on bone growth. Cell Biochem. Funct. 27, 119–127 (2009).
Liu, J. L., Yakar, S. & LeRoith, D. Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc. Soc. Exp. Biol. Med. 223, 344–351 (2000).
Isaksson, O. G., Jansson, J. O. & Gause, I. A. Growth hormone stimulates longitudinal bone growth directly. Science 216, 1237–1239 (1982).
Zezulak, K. M. & Green, H. The generation of insulin-like growth factor-1—sensitive cells by growth hormone action. Science 233, 551–553 (1986).
Wang, J., Zhou, J. & Bondy, C. A. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J. 13, 1985–1990 (1999).
Madsen, K., Friberg, U., Roos, P., Eden, S. & Isaksson, O. Growth hormone stimulates the proliferation of cultured chondrocytes from rabbit ear and rat rib growth cartilage. Nature 304, 545–547 (1983).
Hutchison, M. R., Bassett, M. H. & White, P. C. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology 148, 3122–3130 (2007).
Thomas, A. G., Holly, J. M., Taylor, F. & Miller, V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 34, 944–947 (1993).
Bannerjee, K. et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 38, 270–275 (2004).
Sawczenko, A. et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc. Natl Acad. Sci. USA 102, 13260–13265 (2005).
De Benedetti, F. et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99, 643–650 (1997).
Denson, L. A. et al. Interleukin-6 inhibits hepatic growth hormone signalling via upregulation of Cis and Socs-3. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G646–G654 (2003).
Wong, S. C., Macrae, V. E., McGrogan, P. & Ahmed, S. F. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J. Pediatr. Gastroenterol. Nutr. 43, 144–155 (2006).
Braegger, C. P. et al. Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 16, 49–52 (1993).
Farthing, M. J. et al. Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut 22, 933–938 (1981).
Beattie, R. M. et al. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin. Endocrinol. (Oxf.) 49, 483–489 (1998).
Denson, L. A. et al. TNF-α downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. J. Clin. Invest. 107, 1451–1458 (2001).
D'Mello, S. et al. Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis. Inflamm. Bowel Dis. 18, 236–245 (2012).
Fernandez-Vojvodich, P., Zaman, F. & Savendahl, L. Interleukin-6 acts locally on the growth plate to impair bone growth. Ann. Rheum. Dis. 72, e24 (2013).
MacRae, V. E., Farquharson, C. & Ahmed, S. F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol. 189, 319–328 (2006).
Oguchi, S., Walker, W. A. & Sanderson, I. R. Profile of IGF-binding proteins secreted by intestinal epithelial cells changes with differentiation. Am. J. Physiol. 267, G843–G850 (1994).
De Benedetti, F. et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142, 4818–4826 (2001).
Savage, M. O. et al. IGFs and IGFBPs in GH insensitivity. Endocr. Dev. 9, 100–106 (2005).
Rao, A., Standing, J. F., Naik, S., Savage, M. O. & Sanderson, I. R. Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study. BMJ Open 3, e002737 (2013).
Street, M. E. et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1β and interleukin-6 in inflammatory bowel disease. Horm. Res. 61, 159–164 (2004).
Smith, W. J., Underwood, L. E. & Clemmons, D. R. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J. Clin. Endocrinol. Metab. 80, 443–449 (1995).
Gupta, N., Lustig, R. H., Kohn, M. A., McCracken, M. & Vittinghoff, E. Sex differences in statural growth impairment in Crohn's disease: role of IGF-1. Inflamm. Bowel Dis. 17, 2318–2325 (2011).
Palmert, M. R. & Dunkel, L. Clinical practice. Delayed puberty. N. Engl. J. Med. 366, 443–453 (2012).
Gupta, N., Lustig, R. H., Kohn, M. A. & Vittinghoff, E. Menarche in pediatric patients with Crohn's disease. Dig. Dis. Sci. 57, 2975–2981 (2012).
Azooz, O. G., Farthing, M. J., Savage, M. O. & Ballinger, A. B. Delayed puberty and response to testosterone in a rat model of colitis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1483–R1491 (2001).
DeBoer, M. D., Li, Y. & Cohn, S. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J. Gastroenterol. 45, 277–284 (2010).
Deboer, M. D. & Li, Y. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr. Res. 69, 34–39 (2011).
Deboer, M. D., Steinman, J. & Li, Y. Partial normalization of pubertal timing in female mice with DSS colitis treated with anti TNF α antibody. J. Gastroenterol. 47, 647–654 (2012).
DeBoer, M. D., Barnes, B. H., Stygles, N. A., Sutphen, J. L. & Borowitz, S. M. Changes in inflammation and QoL after a single dose of infliximab during ongoing IBD treatment. J. Pediatr. Gastroenterol. Nutr. 54, 486–490 (2012).
Henderson, P., van Limbergen, J. E., Wilson, D. C., Satsangi, J. & Russell, R. K. Genetics of childhood-onset inflammatory bowel disease. Inflamm. Bowel Dis. 17, 346–361 (2011).
Wine, E. et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 114, 1281–1286 (2004).
Lee, J. J. et al. Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study. Ann. Hum. Genet. 74, 489–497 (2010).
Rioux, J. D. et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet. 66, 1863–1870 (2000).
Russell, R. K. et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 55, 1114–1123 (2006).
Levine, A. et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am. J. Gastroenterol. 100, 1598–1604 (2005).
Heuschkel, R. et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm. Bowel Dis. 14, 839–849 (2008).
Alperstein, G. et al. Linear growth following surgery in children and adolescents with Crohn's disease: relationship to pubertal status. J. Pediatr. Surg. 20, 129–133 (1985).
Lipson, A. B. et al. Acceleration of linear growth following intestinal resection for Crohn disease. Eur. J. Pediatr. 149, 687–690 (1990).
Sanderson, I. R., Udeen, S., Davies, P. S., Savage, M. O. & Walker-Smith, J. A. Remission induced by an elemental diet in small bowel Crohn's disease. Arch. Dis. Child. 62, 123–127 (1987).
Thomas, A. G., Taylor, F. & Miller, V. Dietary intake and nutritional treatment in childhood Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 17, 75–81 (1993).
Newby, E. A., Sawczenko, A., Thomas, A. G. & Wilson, D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD003873 (2005). http://dx.doi.org/10.1002/14651858.CD003873.pub2.
Borrelli, O. et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4, 744–753 (2006).
Heuschkel, R. B., Menache, C. C., Megerian, J. T. & Baird, A. E. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 31, 8–15 (2000).
Sanderson, I. R. The Role of an Elemental Diet in the Management of Children with Crohn's Disease. Thesis, University of London (1989).
Lambert, B., Lemberg, D. A., Leach, S. T. & Day, A. S. Longer-term outcomes of nutritional management of Crohn's disease in children. Dig. Dis. Sci. 57, 2171–2177 (2012).
Cameron, F. L. et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Aliment. Pharmacol. Ther. 37, 622–629 (2013).
Mushtaq, T., Farquharson, C., Seawright, E. & Ahmed, S. F. Glucocorticoid effects on chondrogenesis, differentiation and apoptosis in the murine ATDC5 chondrocyte cell line. J. Endocrinol. 175, 705–713 (2002).
Hokken-Koelega, A. C., Stijnen, T., de Muinck Keizer-Schrama, S. M., Blum, W. F. & Drop, S. L. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation. J. Clin. Endocrinol. Metab. 77, 932–938 (1993).
Leonard, M. B. et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N. Engl. J. Med. 351, 868–875 (2004).
Markowitz, J., Grancher, K., Kohn, N., Lesser, M. & Daum, F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119, 895–902 (2000).
Modigliani, R. et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98, 811–818 (1990).
D'Haens, G. et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116, 1029–1034 (1999).
Borrelli, O. et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36, 342–347 (2004).
Hyams, J. et al. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn's disease in children. Gastroenterology 132, 863–873 (2007).
Hyams, J. S. et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 143, 365–374 (2012).
Malik, S. et al. The effects of anti TNF α treatment with adalimumab on growth in children with Crohn's disease (CD). J. Crohns Colitis 6, 337–344 (2012).
Assa, A. et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J. Crohns Colitis 7, 369–376 (2013).
Crombe, V. et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm. Bowel Dis. 17, 2144–2152 (2011).
Walters, T. D., Gilman, A. R. & Griffiths, A. M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm. Bowel Dis. 13, 424–430 (2007).
Malik, S. et al. Improvement in growth of children with Crohn disease following anti TNF alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J. Pediatr. Gastroenterol. Nutr. 52, 31–37 (2011).
Walters, T. D. et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 146, 383–391 (2014).
Mason, A., Wong, S. C., McGrogan, P. & Ahmed, S. F. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm. Res. Paediatr. 75, 8–13 (2011).
McCaffery, T. D. Jr, Nasr, K., Lawrence, A. M. & Kirsner, J. B. Effect of administered human growth hormone on growth retardation in inflammatory bowel disease. Am. J. Dig. Dis. 19, 411–416 (1974).
Redmond, G. P., Wylie, R. & Michener, W. M. Endocrine therapy in adolescents with Crohns-disease. J. Adolesc. Health 6, 345–345 (1985).
Henker, J. Therapy with recombinant growth hormone in children with Crohn disease and growth failure. Eur. J. Pediatr. 155, 1066–1067 (1996).
Heyman, M. B. et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J. Pediatr. 153, 651–658 (2008).
Calenda, K. A., Schornagel, I. L., Sadeghi-Nejad, A. & Grand, R. J. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm. Bowel Dis. 11, 435–441 (2005).
Vortia, E., Kay, M. & Wyllie, R. The role of growth hormone and insulin-like growth factor-1 in Crohn's disease: implications for therapeutic use of human growth hormone in pediatric patients. Curr. Opin. Pediatr. 23, 545–551 (2011).
Denson, L. A. et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 51, 130–139 (2010).
Wong, S. C. et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. Clin. Endocrinol. (Oxf.) 74, 599–607 (2011).
Jenkins, P. J. et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J. Clin. Endocrinol. Metab. 85, 3218–3221 (2000).
Bortvedt, S. F. & Lund, P. K. Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors. Curr. Opin. Gastroenterol. 28, 89–98 (2012).
Slonim, A. E. et al. A preliminary study of growth hormone therapy for Crohn's disease. N. Engl. J. Med. 342, 1633–1637 (2000).
The work of the author is supported by grants from the National Institutes of Health (P30-DK040561), Crohn's and Colitis Foundation of America (1774) and the Crohn's in Childhood Research Association. The author is grateful to N. Croft, S. Naik and D. van Heel for their comments on the manuscript.
The author declares no competing financial interests.
About this article
Cite this article
Sanderson, I. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol 11, 601–610 (2014). https://doi.org/10.1038/nrgastro.2014.102
IBD phenotype at diagnosis, and early disease-course in pediatric patients in Croatia: data from the Croatian national registry
Pediatric Research (2020)
LPS-induced inflammation disorders bone modeling and remodeling by inhibiting angiogenesis and disordering osteogenesis in chickens
Inflammation Research (2020)
Current Opinion in Endocrine and Metabolic Research (2020)
PM2.5-bound PAHs exposure linked with low plasma insulin-like growth factor 1 levels and reduced child height
Environment International (2020)
Partial enteral nutrition has no benefit on bone health but improves growth in paediatric patients with quiescent or mild Crohn's disease
Clinical Nutrition (2020)